Full Access
Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin
G.K. Daugaard,
J. Petrera,
W. Trojaborg,
G.K. Daugaard
Department of Oncology, The Finsen Institute, Copenhagen.
Search for more papers by this authorJ. Petrera
Department of Clinical Neurophysiology, The National Hospital, Copenhagen, Denmark.
Search for more papers by this authorCorresponding Author
W. Trojaborg
Department of Clinical Neurophysiology, The National Hospital, Copenhagen, Denmark.
*W. Trojaborg, MD, PhD., Department of Clinical Neurophysiology The National Hospital Blegdamsvej 9 Copenhagen DenmarkSearch for more papers by this authorG.K. Daugaard,
J. Petrera,
W. Trojaborg,
G.K. Daugaard
Department of Oncology, The Finsen Institute, Copenhagen.
Search for more papers by this authorJ. Petrera
Department of Clinical Neurophysiology, The National Hospital, Copenhagen, Denmark.
Search for more papers by this authorCorresponding Author
W. Trojaborg
Department of Clinical Neurophysiology, The National Hospital, Copenhagen, Denmark.
*W. Trojaborg, MD, PhD., Department of Clinical Neurophysiology The National Hospital Blegdamsvej 9 Copenhagen DenmarkSearch for more papers by this authorAbstract
Abstract We describe clinical and electrophysiological findings in 8 patients with tumors of germ cell origin before and after treatment with high-dose cisplatin (800–1400 mg) combined with etoposide and bleomycin. All patients developed clinical or electrophysiological signs, or both, of a peripheral sensory neuropathy. One had in addition clinical and electrophysiological signs of CNS involvement, and 2 had a central conduction defect revealed by auditory stimulation.
References
- 1 Rosenberg B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 1973: 60: 399–406.
- 2 Rozencweig M, Von Hoff DD, Slavik M, Muggia FM. Cisdiamminedichloroplatinum (II). A new anticancer drug. Ann Int Medicine 1977: 86: 803–812.
- 3 Becher R, Schutt P, Osieka R, Schmidt CG. Peripheral neuropathy and ophthalomologic toxicity after treatment with cisdichlorodiaminoplatinum II. J Cancer Res Clin Oncol 1980: 96: 219–221.
- 4
Hadley D,
Herr HW.
Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.
Cancer
1979: 44: 2026–2028.
10.1002/1097-0142(197912)44:6<2026::AID-CNCR2820440610>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 5 Kedar A, Cohen ME, Freeman AL. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: A case report. Cancer Treat Rep 1978: 62: 819–821.
- 6 Marin AC, Rierson B. Peripheral neuropathy secondary to cis-dichlorodiammineplatinum (II) (Platinol). Treatment for advanced ovarian cancer. Arizona Med 1979: 36: 898–899.
- 7 Reinstein L, Ostrow SS, Wiernik PH. Peripheral neuropathy after cis-platinum (II)(DDP) therapy. Arch Phys Med Rehabil 1980: 61: 280–282.
- 8 Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982: 39: 719–720.
- 9 Gaustaut JL, Pelissier JF, Jean PH, Tubiana N, Carcassonne Y. Neuropathie periphérique au cisplatine. Une observation. Nouv Presse Med 1982: 11: 1113–1117.
- 10 Panettiere FJ. Cis-platinum toxicity. An analysis based on 3 SWOG studies. Proc Am Assoc Cancer Res 1981: 2: 157.
- 11 Ashraf M, Scotchel PL, Krall JM, Flink EB. Cis-platinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol 1983: 16: 309–318.
- 12 Meier C, Goldhirsch A, Hess Chr, Bazarian J, Greiner R, Beer M. Polyneuropathie nach Cisplatin-Behandlung. Dtsch med Wschr 1985: 110: 721–725.
- 13 Roelofs RF, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984: 34: 934–938.
- 14
Thompson SW,
Davis LAE,
Kornfeld M,
Hilgers RD,
Standefer JC.
Cisplatin Neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.
Cancer
1984: 54: 1269–1275.
10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 15 Cowan JD, Kies MS, Roth JL, Joyce RP. Nerve conduction studies in patients treated with cis-diamminedichloroplatinum (II): a preliminary report. Cancer Treat Rep 1980: 64: 1119–1122.
- 16 Neuwelt EA. Barnett PA, Glasberg M, Frenkel EP: Pharmacology and neurotoxicity of cis-diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic bloodbrain barrier modification. Cancer Res 1983: 43: 5278–5285.
- 17
Berman IJ,
Mann MP.
Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man.
Cancer
1980: 45: 764–766.
10.1002/1097-0142(19800215)45:4<764::AID-CNCR2820450425>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- 18 Ostrow S, Hahn D, Wiernik PH, Richards RD. Ophthalmologic toxicity after cis-dichlorodiammineplatinum (II) therapy. Cancer treat Rep 1978: 62: 1591–1594.
- 19 Clark AW, Parhad IM, Griffin JW, Price DL. Neurotoxicity of cis-platinum: Pathology of the central and peripheral nervous systems. Neurology 1980: 30: 429A.
- 20 Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia. A study by light and electron microscopy and by morphometry. Acta Neuropathol (Berl) 1986: 69: 295–308.
- 21 Nielsen VK. The peripheral nerve function in chronic renal failure, IV. An analysis of the vibratory perception threshold. Acta med scand 1972: 191: 287–296.
- 22
Buchthal F,
Rosenfalck A.
Evoked action potentials and conduction velocity in human sensory nerves.
Brain Res
1966: 3: 1–119.
10.1016/0006-8993(66)90056-4 Google Scholar
- 23 Buchthal F, Rosenfalck A, Trojaborg W. Electrophysiological findings in entrapment of the median nerve at wrist and elbow. J Neurol Neurosurg Psychiat 1974: 37: 340–360.
- 24 Pedersen L, Trojaborg W. Visual, auditory and somatosensory pathway involvement in hereditary cerebellar ataxia. Friedreich's ataxia and familial spastic paraplegia. Electroenceph Clin Neurophysiol 1981: 52: 283–297.
- 25 Cisplatin (Editorial) Lancet 1982: 1: 374–375.
- 26 Rosenfeld CS, Broder LE. Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 1984: 68: 659–660.
- 27 Dewar J, Lunt H, Abernethy DA, Dady P, Haas LF. Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiat 1986: 49: 96–99.
- 28 Gastaut JL, Pellisier JF. Neuropathie au Cisplatine. Etude Clinique, électrophysiologique et morphologique. Rev Neurol (Paris) 1985: 141: 614–626.
- 29 Pages M, Pages AM, Bories-Azeau L. Severe sensorimotor neuropathy after cisplatin therapy. J Neurol Neurosurg Psychiat 1986: 49: 333–4.
- 30 Kaplan RS, Wiernik PH. Neurotoxicity of antineoplastic drugs. Seminars in Oncology 1982: 9: 103–130.
- 31
Falkson G,
Van Dyk JJ,
Van Eden EB,
Van der Merne MB,
Van den Bergh JA,
Falkson HC.
A clinical trial of the oral form of 4′-demethylepipodophyllo-toxin-ß-d ethylidene glucoside (NSC 141540) VP 16–213.
Cancer
1975: 35: 1141–1144.
10.1002/1097-0142(197504)35:4<1141::AID-CNCR2820350418>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 32 Von Hoff DD, Reichert CM, Cuneo R, Reddick R, Gallagher M, Rozencweig M. Demyelination of peripheral nerves associated with cis-diamminedichloroplatinum (II)(DDP) therapy. Proc Am Ass Cancer Res 1979: 20: 91.
- 33 Hemphill M, Pestronk A, Walsh T, Parhed I, Clark A, Rosenshein N. Sensory neuropathy in cis-platinum chemotherapy. Neurology 1980: 30: 429A.
- 34 Schaumburg HH, Spencer PS. Clinical and experimental studies of distal axonopathy – a frequent form of brain and nerve damage produced by environmental chemical hazards. Ann NY Acad Sci 1979: 329: 14–29.
- 35 Cavanagh JB. Sensorimotor neuropathy and cisplatin and adriamycin toxicity. J Neurol Neurosurg Psychiat 1986: 49: 964–5.
